

# Endometrium Cancer Histopathology Reporting Proforma



Mandatory questions (i.e. protocol standards) are in bold (e.g. **S1.01**).

## **S1.01 Identification**

Family name

Given name(s)

Date of birth

Sex

- Male  
 Female  
 Intersex/indeterminate

Ethnicity

- Aboriginal/Torres Strait Islander  
 Other ethnicity  
 Unknown

**G1.01 Patient identifiers**

e.g. MRN, IHI or NHI (please indicate which)

Date of request

**S1.02 Accession number**

Requesting doctor - name and contact details

## **Clinical details**

**S1.03 Principal clinician**

**S1.04 Operative procedure/ specimen**

- Total hysterectomy   
Subtotal hysterectomy   
Radical hysterectomy

**Accompanying specimens**

**G1.04 Clinical diagnosis/ differential diagnoses**

**G1.05 Details of previous biopsies & cytology results (include testing laboratory)**

**G1.06 Details of any previous or current treatment of the present tumour**

**G1.07 Details of any other prior cancer diagnosis**

**G1.08 Details of any family history of cancer**

**S1.05 Metastatic disease?**

- Not stated   
Absent  (on both clinical & operative grounds)  
Present  Pre-operative   
Intra-operative

Details:

**S1.06 Post-operative residual tumour**

Not stated

Absent

Present  Details:

G1.09 Surgeon's specific remarks

**Macroscopic findings**

**S2.04 Lymph nodes**

**SITE 1**

Description

Total number of nodes

Max. diameter/ size range

mm to mm

**SITE 2**

Description

Total number of nodes

Max. diameter/ size range

mm to mm

**SITE 3**

Description

**SITE 3** Total number of nodes

Max. diameter/ size range

mm to mm

**SITE 4**

Description

Total number of nodes

Max. diameter/ size range

mm to mm

**SITE 5**

Description

Total number of nodes

Max. diameter/ size range

mm to mm

**SITE 6**

Description

Total number of nodes

Max. diameter/ size range

mm to mm

**SITE 7**

Description

  

Total number of nodes

Max. diameter/ size range

 mm to  mm**S2.05 Omentum**

Dimensions

 length mm x  width mm x  thickness mm

Proportion of fat replaced by tumour

 % est.

Description

  
**S2.06 Peritoneal biopsies****SITE 1**

Dimensions

 length mm x  width mm x  thickness mm

Description

  
**SITE 2**

Dimensions

 length mm x  width mm x  thickness mm

Description

  
**SITE 3****SITE 3** Dimensions length mm x  width mm x  thickness mm

Description

  
**S2.07 Ovaries****Left Ovary**

Surface

  

Dimensions

 length mm x  width mm x  thickness mm

Description

  
**Right Ovary**

Surface

  

Dimensions

 length mm x  width mm x  thickness mm

Description

  
**S2.08 Fallopian tubes****Left fallopian tube**

Dimensions

(Length x max. diameter)

 length mm x  diameter mm

Description

  
**Right fallopian tube**

Dimensions

(Length x max. diameter)

 length mm x  diameter mm



Distance of cervical tumour from the inferior surgical margin

 mm

Max. depth of cervical wall invasion

 mm

Thickness of normal (uninvolved) cervical wall

 mm

G2.06 Other relevant macroscopic comment

  

## Microscopic findings

### S3.01 Lymph node involvement by tumour

**SITE 1**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to  mm

Extranodal spread

Absent

Present

**SITE 2**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to  mm

Extranodal spread

Absent

Present

**SITE 3**

Number of nodes involved by tumour

Max. dimension of the metastasis or size range

 mm to  mm

Extranodal spread

Absent

Present

**SITE 4**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to  mm

Extranodal spread

Absent

Present

**SITE 5**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to  mm

Extranodal spread

Absent

Present

**SITE 6**

Number of nodes involved by tumour

**SITE 6 Continued**

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to  mm

Extranodal spread

- Absent   
Present

**SITE 7**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to  mm

Extranodal spread

- Absent   
Present

**S3.02 Omental involvement:**

- Tumour free   
Involved

Nature of involvement:

**S3.03 Peritoneal involvement:**

- Tumour free   
Involved

Nature of involvement:

**S3.04 Ovarian involvement:**

- Tumour free   
Involved

Nature of involvement:

**S3.05 Fallopian tubal involvement**

- Tumour free   
Involved

Nature of involvement:

**S3.06 Histological tumour type**

- Endometrioid adenocarcinoma   
and variant   
Mucinous adenocarcinoma   
Serous carcinoma   
Clear cell carcinoma   
Carcinosarcoma   
Undifferentiated carcinoma   
Other Tumour Type

Mixed types of endometrial carcinomas (state all and relative percentages)

and

and

**S3.07 Histological grade for endometrioid carcinomas:**

FIGO

- Grade 1   
Grade 2   
Grade 3   
Grading not applicable

Other grading system

G3.02 Year of publication of grading system

**S3.08 Maximum microscopic depth of myometrial invasion**

 mm

(in histologic slide No: \_\_\_\_\_)

**Normal myometrial wall thickness**

 mm

**S3.09 Lymphovascular invasion**

Absent

Present

At the tumour interface

Remote to the tumour interface

Max. distance from tumour face

mm

**S3.10 Cervical involvement:**

**Involvement of cervical mucosa only**

Absent

Present & in-continuity

Present & separate

**Involvement of cervical stroma**

Absent

Present  in-continuity

separate

Maximum invasive depth

mm

(in histologic slide No: \_\_\_\_\_)

Normal cervical wall thickness

mm

**Cervical vascular involvement**

Absent

Present

**S3.11 Residual non-tumourous endometrium**

Atrophic/cycle phase

Hyperplastic

Atypical hyperplastic

Description (eg polyps)

In situ carcinoma:

Absent

Present

Multicentric/multifocal carcinoma:

Absent

Present

Histological type

Extent

Sites

G3.03 Other relevant microscopic comment

**Ancillary test findings**

G4.01 Histochemical stains

G4.02 Immunohistochemical stains

Positive Abs	<input type="text"/>
Negative Abs	<input type="text"/>
Equivocal Abs	<input type="text"/>

Interpretation

Clinical significance

**Synthesis and overview**

**S5.01 Tumour stage FIGO (see p8)**

**Pathological tumour stage (pTNM)\*\***

T

N

M

**S5.02 Year of publication and edition of cancer staging system**

G5.01 Residual tumour status

RX

R0

R1

R2

G5.02 Diagnostic summary

Include: operative procedure/specimen type; tumour type and stage; residual tumour status

**S5.03 Other relevant comments**


**Tumour stage FIGO & pTNM##**

Primary Tumour (T) (Surgical-Pathologic Findings)		
TNM	FIGO	
TX		Primary tumour cannot be assessed
T0		No evidence of primary tumour
Tis*		Carcinoma in situ (preinvasive carcinoma)
T1	I	Tumour confined to corpus uteri
T1a	IA	Tumour limited to endometrium or invades less than one-half of the myometrium
T1b	IB	Tumour invades one-half or more of the myometrium
T2	II	Tumour invades stromal connective tissue of the cervix but does not extend beyond uterus**
T3a	IIIA	Tumour involves serosa and /or adnexa (direct extension or metastasis)
T3b	IIIB	Vaginal involvement (direct extension or metastasis) or parametrial involvement.
T4	IVA	Tumour invades bladder mucosa and /or bowel mucosa (bullous oedema is not sufficient to classify a tumour as T4)
Regional Lymph Nodes (N)		
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N1	IIIC1	Regional lymph nodes metastasis to pelvic lymph nodes
N2	IIIC2	Regional lymph nodes metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.
Distant Metastasis (M)		
M0		No distant metastasis
M1	IVB	Distant metastasis (includes metastasis to inguinal lymph nodes intraperitoneal disease, or lung, liver, or bone. It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa.

\* Note: FIGO no longer includes Stage 0(Tis)

\*\* Endocervical glandular involvement only should be considered Stage I and not as Stage II.

## Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com.

Worksheet prepared by:

On: